|
Originally published In Press as doi:10.1074/jbc.M104942200 on September 26, 2001
J. Biol. Chem., Vol. 276, Issue 48, 44464-44471, November 30, 2001
Signal Transduction Pathways Mediating Neurotensin-stimulated
Interleukin-8 Expression in Human Colonocytes*
Dezheng
Zhao,
Andrew C.
Keates ,
Sabina
Kuhnt-Moore,
Mary
P.
Moyer§,
Ciaran P.
Kelly, and
Charalabos
Pothoulakis¶
From the Division of Gastroenterology, Beth Israel Deaconess
Medical Center, Harvard Medical School, Boston, Massachusetts 02215 and § INCELL Corporation, San Antonio, Texas 78249
Received for publication, May 30, 2001, and in revised form, August 14, 2001
 |
ABSTRACT |
Neurotensin (NT), a neuropeptide released in the
gastrointestinal tract in response to several stimuli, is involved in
the pathophysiology of colonic inflammation. However, the molecular mechanism(s) mediating this proinflammatory response remains unclear. We found that NCM460, non-transformed human colonocytes, express a
functional high affinity NT receptor that mediates NT-induced Erk
activation. By using NCM460 cells stably transfected with NTR1, we show
that NTR1 activation leads to interleukin (IL)-8 secretion that is
mediated via both NF- B- and Erk-dependent pathways. In
addition, NT-stimulated NF- B activation is dependent on
intracellular calcium release. NT-stimulated Erk activity requires Ras
activation because overexpression of the dominant negative Ras mutant
Ras-17N almost completely inhibits the Erk activation. Furthermore, NT directly stimulates Ras-GTP formation as shown by a Ras-GTP pull-down assay. By using reporter gene constructs containing targeted
substitutions in the IL-8 promoter, we show that the NF- B, AP-1, and
to a lesser degree the C/EBP sites in the IL-8 promoter region are
required for IL-8 gene expression induced by NT. In summary, our
results demonstrate that NT stimulates calcium-dependent
NF- B and Ras-dependent Erk pathways that mediate the
release of IL-8 from non-transformed human colonocytes. We speculate
that these NT-related proinflammatory pathways are important in the
pathophysiology of colonic inflammation.
 |
INTRODUCTION |
Neurotensin (NT),1 a
13-amino acid neuropeptide originally isolated by Carraway and Leeman
(1), is highly expressed in the gastrointestinal tract (2). In the
ileal mucosa NT is synthesized and secreted by specific endocrine cells
(3), in response to diverse stimuli (4). NT increases small bowel,
colonic, and gastric motility and stimulates ileal, pancreatic, and
biliary secretion (4, 5) as well as Cl secretion from
human colonic mucosa (6), indicating that this peptide may contribute
to the pathophysiology of human diarrhea. NT also stimulates growth of
the intestinal mucosa under physiological and pathological conditions
and causes proliferation of intestinal epithelial cells in
vivo and in vitro (7-11). Two G-protein-coupled receptors (GPCRs) have been described for NT, a high affinity (NTR1)
and a low affinity (NTR2) receptor (12). Administration of the specific
NTR1 antagonist SR 48692 to rats inhibits colonic mucin and
prostaglandin E2 secretion in response to immobilization stress (13), suggesting the importance of NTR1 in stress-mediated colonic responses. Our recent studies (14) demonstrate that NT is a
proinflammatory peptide in the colon because blockage of the NT-NTR1
interaction with SR 48692 inhibited colonic secretion and inflammation
mediated by Clostridium difficile toxin A. We also showed
that, compared with normal colonic epithelial cells, there was a
dramatic up-regulation of NTR1 during human colonic inflammation (15)
as well as in Clostridium difficile toxin A-mediated colitis
(14). NT exerts its proinflammatory effects by interacting with several
cell types, including mast cells (13, 14, 16, 17), leukocytes (14, 18),
endothelial cells (19), and macrophages (20).
The intracellular events stimulated by NT have been studied previously
in human colon and pancreatic cell lines that express endogenous NTR1
(21, 22). NT stimulates the formation of inositol 1,4,5-trisphosphate,
increases intracellular calcium (23, 24), and activates Erk, a member
of the mitogen-activating protein kinase family (25), in colonic
adenocarcinoma HT29 cells and in pancreatic MIA PaCa-2 cells (22). NT
also stimulates Erk activation in Chinese hamster ovary cells
overexpressing NTR1, which is partially inhibited by PTX and completely
blocked by the protein kinase C inhibitor GF 109203X (25). Although NT triggers calcium release and Erk activation, their involvement in
NT-induced release of proinflammatory cytokines has not been studied.
In addition, the signaling pathways stimulated by NT that lead to Erk
activation have not been elucidated.
Studies in human intestinal microvascular endothelial cells showed that
NT stimulates translocation and DNA binding activity of NF- B (15).
NF- B is a transcriptional factor critical for expression of genes
involved in inflammation of the gastrointestinal tract (26-28). It
consists of homo- and heterodimers of Rel family proteins, typically
p65 and p50, sequestered in an inactive form in the cytoplasm by I B
inhibitory proteins. Upon stimulation, I Bs become phosphorylated,
ubiquitinate, and subsequently degraded, resulting in the nuclear
translocation of NF- B and the activation of NF- B-responsive
genes. NF- B has been shown to be essential for expression of
inflammatory genes such as IL-8. IL-8, a potent chemotactic factor for
neutrophils, basophils, and T lymphocytes, has been implicated in the
pathogenesis of several gastrointestinal inflammatory states (29-33).
Three cis-regulatory elements (AP-1, C/EBP-like, and B-like sites)
in the IL-8 promoter region are involved in IL-8 gene expression (34,
35). However, the relative importance of the sites in regulating IL-8
gene expression depends on the cell type and the particular stimulus.
In this study, we utilized NCM460, a non-transformed human colonic
epithelial cell line, to investigate the molecular mechanisms by which
NT exerts its proinflammatory effects. We found that NCM460 cells
express a functional NTR1 receptor. Exposure of NCM460 cells
transfected with the NTR1 to NT stimulates IL-8 secretion as well as
gene transcription in a time- and dose-dependent manner. We
also demonstrate that NF- B and Erk activation are required for
NT-induced IL-8 gene expression. Our results indicate that NT-stimulated NF- B DNA binding activity is
calcium-dependent. More importantly, we show for the first
time that NT stimulates Ras-GTP formation and that NT-induced Erk
activation is Ras-dependent.
 |
EXPERIMENTAL PROCEDURES |
Reagents
NT was purchased from Phoenix Pharmaceuticals (Belmont, CA).
[3,11,-tyrosyl-3,5-3H]NT was from PerkinElmer
Life Sciences. BAPTA/AM and sulfasalazine were obtained from
Calbiochem. Sulfinpyrazone and collagenase were from Sigma, and Fura-2
AM and Pluronic F127 were from Molecular Probes (Eugene, OR). DNA
mini-prep kits were from Qiagen (Valencia, CA). NCM460 cells and
culture medium M3D were obtained from INCELL Corporation (San Antonio,
TX). BCA reagents for measurement of protein concentration were
purchased from Pierce.
Creation of a Stably Transfected Human Colonic NCM460 Cell Line
Expressing NTR1 (NCM460-NTR1)
Construction and Functionality of a Puromycin-resistant
Retroviral Vector--
To create stably transfected cell lines that
selectively grow in medium containing puromycin, we constructed a
highly efficient puromycin-resistant expression retroviral vector named
pCMBP from the vector pCMMP (kindly provided by Dr. Richard C. Mulligan, Children's Hospital, Harvard Medical School) and pBabe-puro
(kindly provided by Dr. Steve R. Farmer, Boston University School of
Medicine). The retroviral promoter from pCMMP was removed with the
restriction enzymes Sbf and PmlI (the fragment
named Sbf-PmlI), and then ligated into the pBabe-puro vector
which was first digested with BamHI, end-blunted with
Klenow, and digested with PstI. To test the functionality of
this vector, we also ligated a bacterial -galactosidase gene (lacZ) into the pCMBP vector, by a three-fragment ligation.
To achieve that, pBabe-puro was first digested with PstI and
EcoRI to remove the entire Moloney murine leukemia virus
5'-long terminal repeat and adjacent sequence. A LacZ fragment was
isolated from pBluescript-lacZ by first digesting this plasmid with
BamHI, end-blunting with Klenow, and then digesting with
EcoRI. The digested vector was then ligated with the
fragment Sbf-PmlI and the LacZ fragment. The
retroviruses expressing -galactosidase were prepared following the
procedure described below and used to infect NIH3T3 cells to measure
the titer of produced viruses.
Cloning of Full-length Human NTR1 cDNA from NCM460 Cells,
Construction of NTR1-expressing Retroviral Vectors--
Total cell RNA
was isolated from NCM460 cells by the guanidinium
isothiocyanate/phenol/chloroform extract procedure as described previously (36). Two micrograms of RNA were reverse-transcribed with
Moloney murine leukemia virus-reverse transcriptase (Invitrogen, Grand Island, NY) according to the manufacturer's instruction. Then 2 µl of RT mix was used for PCR amplification of full-length human NTR1
cDNA using Taq DNA polymerase (Qiagen) under the
following conditions: 94 °C, 4 min followed by 35 cycles of
94 °C, 1 min; 60 °C, 1 min and 72 °C, 1 min and then 72 °C,
5 min. The primers were designed based on the published sequence of
human NTR1 (GenBankTM accession number X70070; Ref. 37).
The forward primer containing an EcoRI site was
5'-agtgaattcGGACTCCAGCGCCCACCATGC-3'; and the reverse primer
containing a BamHI site was
5'-taaggatccACACGTTCCGGGGCGCACAGC-3'. A 1315-bp fragment was subcloned
into pCR2.1 vector using the TA cloning kit (Invitrogen), and the
identity of the DNA was confirmed by DNA sequencing. The NTR1 fragment
was then removed from pCR2.1 by EcoRI digestion and ligated
into the puromycin-expressing retroviral vector pCMBP (pCMBP-NTR1)
described above. Retroviruses containing NTR1 were prepared using
pCMBP-NTR1 following the procedure described below.
Preparation of Retroviruses and Infection of NCM460
Cells--
293T cells (kindly provided by Dr. Richard A. Mulligan)
were seeded at a density of 4-5 × 106 cells in
100-mm plates containing 10 ml of 10% FBS/Dulbecco's modified
Eagle's medium for 24 h, and the medium was replaced with fresh
medium 4 h before transfection. The plasmids pMD-gag-pol, pMD-VSVG
(both kindly provided by Dr. Richard C. Mulligan), and pCMBP-NTR1 were
combined in a ratio of 3:1:4 and used to prepare transfection mixtures
using Effectene Transfection Reagent (Qiagen) according to the
manufacturer's instructions. Forty eight hours after transfection, the
media were collected and filtered through 0.45-µm disc filters, and
the supernatants were either used immediately or stored at 80 °C.
Infection of NCM460 cells was carried out as follows. Cells were seeded
at 4 × 104 cells/cm2 culture surface for
24 h and incubated with medium containing 2 volumes of filtered
virus-containing supernatant and 1 volume of fresh growth media for
16-24 h in the presence of 10 µg/ml Polybrene (Sigma). The infected
cells were then incubated in media containing 10% FBS and 2 µg/ml
puromycin for 6 days. Positively selected cells were pooled (named
NCM460-NTR1 cells) and used for this study.
Ligand Binding Assay
NCM460 cells or NCM460-NTR1 cells in 24-well plates were
incubated in M3D media containing 10% FBS until they reached ~80% confluence. The cells were then washed once with PBS and incubated with
M3D media for 24 h. The cells were incubated with 0.3 ml of fresh
M3D media containing increasing concentrations of
[3,11,-tyrosyl-3,5-3H]NT (0.05-20
nM). To determine nonspecific binding, 1 µM
NT was added to the incubation mixture. After incubation for 3 h
at 4 °C, the cells were placed on ice and washed three times with
cold PBS. Cells were then lysed in 0.3 ml of 0.3 M NaOH for
30 min at 37 °C, and the radioactivity in the lysate was measured to determine the amount of ligand bound. All determinations were performed
in triplicate. The number of receptors was determined from a saturation
curve generated by SigmaPlot 3.0 software (Jandel Scientific, San
Raphael, CA).
IL-8 Measurements
IL-8 protein levels in colonic epithelial cell-conditioned media
were determined by a double-ligand enzyme-linked immunosorbent assay
(ELISA) using goat anti-human IL-8 (R & D Systems Inc.) as described
previously (30). Results were expressed as mean ± S.E. (ng/ml).
At least three independent experiments were performed for each
experimental condition, each with triplicate measurements.
Construction of Human IL-8 Promoter-Luciferase Constructs and
Luciferase Assay
Construction of a reporter construct containing 1521 bp
(nucleotides 1481 to +40) of the promoter region of human IL-8 gene has been described previously (31). IL-8 reporter constructs containing
mutations in NF- B, AP-1, or C/EBP sites were created by overlapping
PCR-based site-directed mutagenesis. The substitution mutants were
based on the sequences described by Wu et al. (35). The
mutated NF- B sequence was cgTTAACTTTCCtct; the mutated AP-1 sequence
was gaTATCTCAgg; and the mutated C/EBP sequence was tcAGCTACGAGTcg. The
sequences were confirmed by DNA sequencing using primers specific for
the pGL2-basic luciferase expression vector (GL primers 1 and 2;
Promega Corp., Madison, WI). To determine the IL-8 promoter activity in
response to NT, cells were seeded in 12-well plates (0.2 × 106 cells/well) overnight and transiently transfected using
Effectene Transfection Reagent (Qiagen) with IL-8 promoter-luciferase
constructs or a control luciferase construct pRL-TK (Promega) or other
DNA constructs as indicated. Transfected cells were serum-starved for
24 h followed by exposure to NT for 4 h. Firefly and
Renilla luciferase activities in cell extracts were measured
using Dual-Luciferase Reporter Assay System (Promega). The relative
luciferase activity was then calculated by normalizing IL-8
promoter-driven firefly luciferase activity to control
Renilla luciferase activity. Data from all experiments are
presented as the relative luciferase activity (mean ± S.E.) from
at least two independent sets of experiments, each with triplicate measurements.
Electrophoretic Mobility Shift Assays (EMSA)
Nuclear extracts were prepared for DNA binding assays as
described previously (38). Cells growing in 100-mm plates were washed
2× with ice-cold PBS and then collected into 1 ml of TNE buffer (40 mM Tris (pH 7.4), 1 mM EDTA, 0.15 M
NaCl) and centrifuged at 5000 × g for 10 s. The
cell pellets were incubated with 800 µl of buffer A (10 mM Hepes (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.5 mM
phenylmethylsulfonyl fluoride) for 10 min before addition of 46 µl of
10% Nonidet P-40 for an additional 2 min. Nuclei were pelleted by
centrifugation at 5000 × g for 10 s, incubated
with 120 µl of buffer B (20 mM Hepes (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 0.1 mM phenylmethylsulfonyl fluoride) for 45 min, and
centrifuged at 13,000 × g for 10 min. Ten micrograms
of nuclear extracts were incubated with 3 µg of poly(dI-dC)
(Promega), 2 µl of bandshift buffer (50 mM
MgCl2, 340 mM KCl), and 8 µl of delta buffer
(0.1 mM EDTA, 40 mM KCl, 25 mM
Hepes (pH 7.6), 8% Ficoll 400, 1 mM dithiothreitol) at
4 °C for 15 min. 32P-Labeled double-stranded
oligonucleotide probe (100,000 cpm) was then added to the reaction
mixture and incubated for 30 min on ice. For supershift assays, the
appropriate antibody was added to the nuclear extract and incubated at
4 °C for 30 min before addition of the probe. The anti-NF- B p65
and anti-p50 as well as normal rabbit IgG (control antibody) were from
Santa Cruz Biotechnology (Santa Cruz, CA). Binding of specific nuclear
protein to the probe was determined by fractionating the nuclear
proteins through a nondenaturing 6% polyacrylamide gel at 200 V for
2 h at room temperature in TBE buffer (80 mM Tris
borate, 2 mM EDTA (pH 8.0)). The gel was dried at 80 °C
for 2 h under vacuum before exposure to x-ray autoradiography
film. The NF- B consensus oligonucleotide was purchased from Promega.
The double-stranded oligonucleotide was end-labeled by T4 DNA
polynucleotide kinase (New England Biolabs, Beverly, MA) and
[ -32P]ATP (PerkinElmer Life Sciences).
Intracellular Ca2+ Release
Serum-starved cells grown in 100-mm plates were washed twice
with PBS and incubated with 4 ml of collagenase solution (0.2 mg/ml
collagenase, 0.2 mg/ml soybean trypsin inhibitor, 1 mg/ml bovine serum
albumin, 2 mM EDTA in PBS) at 37 °C for 30 min. Cells were detached by gentle scraping and centrifuged at 1000 rpm for 3 min.
Cell pellets were resuspended in 2 ml of Ca2+ buffer (5 mM KCl, 140 mM NaCl, 1 mM
CaCl2, 1 mM MgCl2, 5.6 mM glucose, 0.1% bovine serum albumin, 0.25 mM
sulfinpyrazone, and 10 mM Hepes (pH 7.5)) and centrifuged
again at the same speed. Cell pellets were resuspended in 2 ml of
Ca2+ buffer containing 1 µg/ml Fura-2 and 0.02% pluronic
F-127 and incubated at 37 °C for 30 min. Cells were then collected,
centrifuged at 1100 rpm for 3 min, and resuspended in 2 ml of
Ca2+ buffer. Half of the cell suspension was preincubated
with Me2SO vehicle or BAPTA/AM (50 µM) for 5 min before stimulation with NT. Intracellular Ca2+
concentration was measured with the DeltaScan Illumination System plus
Felix software (Photon Technology International, Lawrenceville, NJ).
Erk Phosphorylation Assay
Cells were washed twice with ice-cold PBS and then incubated in
RIPA buffer containing a protease inhibitor mixture (Roche Molecular
Biochemicals) for 10 min. Cell lysates were centrifuged at 1000 × g for 10 min. Equal amounts of cell extracts were separated by SDS-polyacrylamide gel electrophoresis (10%), and proteins were
transferred onto nitrocellulose membranes (Bio-Rad) at 100 V for 1 h at 4 °C. Membranes were blocked in 5% nonfat, dried milk in TBST
(50 mM Tris (pH 7.5), 0.15 M NaCl, 0.05% Tween
20) and then incubated with phosphospecific antibodies (0.2 µg/ml) to
Erk 1/2 (New England Biolabs, Beverly, MA). Horseradish
peroxidase-labeled antibodies were detected by SuperSignal
Chemiluminescent Substrate (Pierce).
Ras Activation Assay
Ras activity was measured using a Ras Activation Assay Kit
(Upstate Biotechnology Inc., Lake Placid, NY) following the
manufacturer's instructions. Briefly, quiescent cells were stimulated
with NT (10 7 M), washed 2× with ice-cold
PBS, and then incubated with 1× Mg2+ lysis/washing buffer
containing a protease inhibitor mixture (Roche Molecular Biochemicals)
for 10 min at 4 °C. Cell lysates were centrifuged at 1000 × g for 10 min. The supernatants were then pretreated with
glutathione-Sepharose-4B beads (Amersham Pharmacia Biotech) for 30 min
and then centrifuged at 1000 × g for 10 min. The
supernatants were incubated with Raf-1-RBD-conjugated agarose beads for
30 min at 4 °C, and the beads were washed 3× with 1×
Mg2+ lysis buffer. The beads were then boiled with 1× SDS
sample buffer, and equal volumes of the samples were subjected to
Western blot analysis using a monoclonal antibody against Ras. To
normalize the amount of GTP-bound Ras to total amount of Ras, equal
volumes of cell lysate were also subjected to Western blot analysis
using the Ras monoclonal antibody.
Statistical Analyses
Results were expressed as means ± S.E. Data were analyzed
using the SIGMA-STATTM professional statistics software
program (Jandel Scientific Software, San Rafael, CA). Analyses of
variance with protected t test were used for intergroup comparison.
 |
RESULTS |
NT Stimulates IL-8 Secretion and Gene Transcription in NCM460-NTR1
Cells--
Our recent work (14) demonstrated that NTR1 mediates
colonic inflammation. To examine whether NTR1 mediates release of the proinflammatory cytokine IL-8, we used the non-transformed human colonic epithelial cell line, NCM460 (39). We first determined whether
NCM460 cells express NTR1 mRNA by RT-PCR, and we examined the
functionality of this receptor. Our results show that the NCM460 cells
express NTR1 as indicated by an expected 1315-bp PCR product that
corresponds to the full-length coding region of human NTR1 cDNA
(data not shown). Moreover, when quiescent NCM460 cells were exposed to
NT (10 10 to 10 6 M) for 10 min,
NT induced Erk phosphorylation even at a concentration of
10 10 M (Fig.
1a). Pretreatment with the
specific NTR1 antagonist SR 48692 at a concentration of 10 nM completely inhibited NT (10 nM)-induced Erk
activation, indicating that NTR1 mediates this response (Fig.
1b). NT (10 6 M, 4-24 h
of exposure), however, failed to stimulate IL-8 secretion (data not
shown), suggesting that the levels of the receptor may not be high
enough to mediate this response. Therefore, we sought to overexpress
NTR1 in NCM460 cells to examine whether increased expression of NTR1
results in IL-8 secretion in response to NT. To do that, the NTR1
cDNA fragment generated by RT-PCR from total mRNA derived from
NCM460 cells was subcloned into the retroviral vector pCMBP.
Retroviruses expressing NTR1 were produced and used to generate stably
transfected NCM460 cell lines expressing NTR1 (NCM460-NTR1) as
described under "Experimental Procedures." To find out whether
NCM460-NTR1 cells express increased number of NT receptors, we
performed a ligand binding assay using [3H]NT. The
results (data not shown) demonstrated that compared with the parental
NCM460 cell that expressed 24,000 NT receptors per cell, NCM460-NTR1
cells had ~360,000 receptors per cell.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 1.
NT stimulates IL-8 secretion and gene
transcription in nontransformed human colonocytes overexpressing
NTR1. a, NCM460 cells were incubated in M3D media for
24 h to render cells quiescent and then stimulated with NT
(10 10 to 10 6 M) for 10 min.
Cell lysates were resolved by SDS-polyacrylamide gel electrophoresis
and immunoblotted with anti-phospho-Erk1/2 (upper panel) and
anti-Erk2 (lower panel); the latter was used as a protein
loading control. b, quiescent NCM460 cells were pretreated
with NTR1-specific antagonist SR 48692 (1-50 nM) for 10 min and then treated with NT (10 nM) for 10 min. Erk
phosphorylation was measured as in a. c, NCM460
cells stably transfected with NTR1 (NCM460-NTR1) were incubated with
M3D media for 24 h and then treated with NT (10 7
M) for the indicated time points. The conditioned media
were collected and IL-8 was measured by ELISA. Asterisk
indicates p < 0.001, 2-h NT-stimulated cells
versus non-stimulated cells. d, NCM460 cells or
NCM460-NTR1 cells were rendered quiescent and treated for 4 h with
NT at the indicated concentrations, and IL-8 was measured in the
conditioned media by ELISA. Asterisk indicates
p < 0.01, 10 9 M
NT-stimulated cells versus non-stimulated cells. Results are
expressed as mean ± S.E. (ng/ml). e, NCM460 cells or
NCM460-NTR1 cells were transfected with IL-8 promoter construct with an
internal control plasmid as described under "Experimental
Procedures." Cells were serum-starved and then treated with NT
(10 7 M) for 4 h. Cell extracts were
prepared to measure IL-8 promoter activity that was expressed as
mean ± S.E. (relative luciferase activity, n = 3). Asterisk indicates p < 0.001, 10 7 M NT-stimulated cells versus
non-stimulated cells. Results are from a single experiment each with
triplicate determinations, representative of three separate
experiments.
|
|
Exposure of NCM460-NTR1 cells to NT (10 7 m)
strongly stimulated IL-8 secretion with a maximal induction 4 h
after NT exposure (Fig. 1c). IL-8 secretion induced by NT
was dose-dependent at concentrations ranging between
10 10 and 10 6 M, and a
significant (1.6-fold, p < 0.01) induction was
obtained at 10 9 M (Fig. 1d).
However, NT (10 6
M, 4 h of
exposure) could not stimulate IL-8 secretion in the parental NCM460
cells (Fig. 1d). We also determined whether NT
stimulates IL-8 gene transcription in quiescent NCM460-NTR1 cells
transiently transfected with a luciferase reporter construct containing
the human IL-8 promoter. The results showed that NT (10 7
M) significantly stimulated IL-8 promoter-driven luciferase
activity by 31-fold in NCM46-NTR1 cells but had no effect in the
parental NCM460 cells (Fig. 1e, left).
Taken together, these results demonstrate that NT stimulates IL-8
secretion as well as IL-8 gene transcription in NCM460-NTR1 cells.
NT-induced IL-8 Expression Requires NF- B Activation--
To
confirm the requirement of NF- B activation for NT-induced IL-8
secretion, we examined whether NT stimulated nuclear translocation and
DNA binding activity of NF- B in NCM460-NTR1 cells. NT
(10 7 M) dramatically increased DNA binding of
a nuclear protein complex that contained NF- B p65 and p50 subunits
as shown by supershift assays (Fig.
2a). The specificity of the
shifted band was confirmed by preincubating the nuclear extract with a
control antibody that did not bind NF- B as well as by addition of
excess unlabeled (cold) probe into the binding mixture (Fig.
2a).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 2.
NT-induced IL-8 expression requires
NF- B activation. a, quiescent
NCM460-NTR1 cells were treated with NT (10 7
M) for 30 min, and nuclear extracts were prepared for EMSA
using a 32P-labeled NF- B probe as described under
"Experimental Procedures." For supershift assays, 2 µg of
anti-p65, anti-p50, or normal rabbit IgG were preincubated with nuclear
extracts for 30 min on ice before EMSA reactions were performed.
b, quiescent cells were pretreated with sulfasalazine (2 mM) for 30 min and then exposed to NT (10 7
M) for 30 min, and NF- B binding activity was examined by
EMSA. c, NCM460-NTR1 cells were infected with I B - or
-galactosidase (lacZ)- expressing retroviruses and
incubated with M3D media for 24 h before treatment with NT
(10 7 M) for 4 h for measurement of IL-8
secretion. Asterisk indicates p < 0.01, I B -expressing cells versus LacZ-expressing cells with
NT stimulation. d, NCM460-NTR1 cells were transfected with
IL-8 promoter construct with an internal control plasmid and pCMBP-lacZ
or pCMBP-I B . Cells were incubated with M3D media for 24 h
and then treated with NT (10 7 M) for 4 h. Cell extracts were prepared to measure IL-8 promoter activity which
was expressed as mean ± S.E. (relative luciferase activity,
n = 3). Asterisk indicates p < 0.01, I B -expressing cells versus LacZ-expressing
cells with NT stimulation. e, cells were transiently
transfected with wild-type or NF- B mutant promoter constructs
together with a control luciferase construct. The transfected cells
were incubated with media for 24 h and then exposed to NT
(10 7 M) for 4 h. Cell extracts were
prepared to determine luciferase activity as described under
"Experimental Procedures." The results were representative of three
separate experiments.
|
|
We next determined whether inhibition of NF- B activation blocks
NT-induced IL-8 secretion. Pretreatment of NCM460-NTR1 cells with the
NF- B inhibitor sulfasalazine significantly inhibited NT-induced
NF- B DNA binding activity (Fig. 2b) and IL-8 secretion (data not shown). To confirm the role of NF- B in NT-induced IL-8 expression, we overexpressed I B , an endogenous NF- B inhibitor. Our data show that NT-induced IL-8 secretion was reduced by 65% in
cells overexpressing human I B , as compared with the control (Fig.
2c). To examine whether overexpression of I B inhibits NT-induced IL-8 gene transcription, NCM460-NTR1 cells were transiently transfected with the IL-8 luciferase reporter construct together with
an I B plasmid or control vector. Our data clearly indicate that
cotransfection with the I B plasmid significantly reduced NT-induced IL-8 promoter-driven gene transcription (Fig.
2d). To confirm the NF- B requirement for NT-induced IL-8
transcription, we used an IL-8 promoter construct that contained
targeted mutations in the NF- B-binding site. The results showed that
the NF- B mutant construct did not respond to NT treatment, whereas
the wild-type IL-8 promoter construct was strongly activated by NT
(Fig. 2e). Thus, NF- B activation is a major requirement
for NT-induced IL-8 gene transcription and IL-8 protein release.
Calcium Dependence of NT-induced NF- B Activation and
IL-8 Secretion--
NT (10 7 M) stimulated
intracellular calcium release in NCM460-NTR1 cells within a few
seconds, which returned to control values after ~3 min (Fig.
3a). Moreover, pretreatment of
the cells with BAPTA/AM completely inhibited NT-induced
Ca2+ release, even below the basal levels (Fig.
3a), and abolished NT-induced IL-8 secretion (Fig.
3b). To find out whether the effect of BAPTA/AM was mediated
through NF- B, quiescent NCM460-NTR1 cells were preincubated with
BAPTA/AM and then treated with NT (10 7 M),
and NF- B DNA binding activity was measured by EMSA. Our results
showed that pretreatment with BAPTA/AM significantly attenuated NT-stimulated NF- B DNA binding activity, indicating that the effect
of intracellular calcium on NT-induced IL-8 secretion involves NF- B activation (Fig. 3c). We also found that
preincubation of NCM460-NTR1 with 20 µM W7, a
Ca2+-calmodulin antagonist, or 10 µM of
cyclosporin A, an inhibitor of the calcium-dependent
phosphatase calcineurin, inhibited NT-induced IL-8 secretion by 61.3 and 60.7%, respectively (p < 0.05, n = 3) (data
not shown). These results suggest that the
Ca2+-dependent NF- B activation in response
to NT might be mediated through Ca2+-activated kinase(s)
and phosphatase(s).

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 3.
Calcium mobilization is essential for
NT-induced NF- B activation and IL-8
secretion. a, quiescent NCM460-NTR1 cells were
collected from 100-mm plates to determine intracellular calcium release
as described under "Experimental Procedures." The cell suspensions
were pretreated with Me2SO or BAPTA/AM (50 µM) for 5 min before stimulation with NT. b,
cells were pretreated with BAPTA/AM (B/A) (25, 50 µM) for 30 min, treated with NT (10 7
M) for 4 h, and IL-8 release measured in the
conditioned media. c, cells were pretreated with BAPTA/AM
(50 µM) for 30 min and treated with NT (10 7
M) for 30 min. Nuclear extracts were then prepared, and
NF- B DNA binding activity was determined by EMSA. Results are
representative of three separate experiments.
|
|
Erk Activation Is Required for NT-induced IL-8 Expression--
We
next determined whether an Erk-dependent pathway mediates
NT-induced IL-8 expression. Quiescent cells were pretreated with PD98059, a specific MAP kinase/Erk kinase inhibitor, and treated with
NT (10 7 M) for 4 h to measure IL-8
release and IL-8 promoter-dependent transcription. PD98059
significantly inhibited both NT-induced IL-8 release (Fig.
4a) and IL-8 promoter activity
(Fig. 4b), suggesting that Erk activation is involved in
NT-induced IL-8 expression.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 4.
Erk activation is required for NT-induced
IL-8 expression. a, quiescent NCM460-NTR1 cells were
pretreated with PD98059 (50 µM) for 30 min and treated
with NT (10 7 M) for 4 h. Conditioned
media were then collected for measurement of IL-8 by ELISA.
Asterisk indicates p < 0.01, PD98059-treated cells with NT stimulation versus control
cells with NT stimulation. b, cells were transfected with
wild-type IL-8 promoter construct and serum-starved as described under
"Experimental Procedures." Cells were then pretreated with PD98059
(50 µM) for 30 min and treated with NT (10 7
M) for 4 h. Cell extracts were made to determine
luciferase activity. Asterisk indicates p < 0.001, PD98059-treated cells with NT stimulation versus
control cells with NT stimulation. The results were representative of
three individual experiments, each with triplicate
determinations.
|
|
NT Stimulates Ras-GTP Formation--
To examine whether Ras is
upstream of NT-induced Erk activation, we first examined whether NT
directly activates Ras using a Ras-GTP pull-down assay (40). Quiescent
MCM460-NTR1 cells were treated with NT (10 7
M) for various times or EGF for 3 min, and the levels of
Ras-GTP in the cell extracts were then measured. We found that NT
increased Ras-GTP loading from 3 to 5 min after NT exposure. As
expected, EGF (100 ng/ml) strongly stimulated Ras-GTP loading (Fig.
5). These data demonstrate for the first
time that binding of NT to NTR1 activates Ras.

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 5.
NT stimulates Ras-GTP formation.
Quiescent cells were treated with NT (10 7 M)
for the indicated times. Cell extracts were then prepared, and equal
amounts of protein were used to measure the levels of GTP-bound Ras as
described under "Experimental Procedures." Equal amount of cell
extracts were also subjected to Western blot analysis using the
monoclonal antibody directed against Ras to confirm equal protein
loading.
|
|
NT-induced Erk Activation Is Ras-dependent--
It is
known that GPCR-stimulated Erk activation can be
Ras-dependent or Ras-independent (41, 42). However, whether
Ras is involved in the NT signaling pathway is not known. To explore this possibility, we used a dominant negative Ras mutant Ras-17N to
block downstream events of Ras activation. NCM460-NTR1 cells were
infected with the Ras-17N-expressing retroviruses and then rendered
quiescent. Cells were then exposed to either NT (10 7
M) or PMA (2 µM), a phorbol ester that
activates Erk in a Ras-independent manner (43), or EGF (100 ng/ml),
which is known to activate Erk in a Ras-dependent manner.
We found that the dominant negative Ras mutant blocked Erk activation
induced by NT and, as expected, by EGF (Fig.
6) but had no effect on PMA-induced Erk
activation (Fig. 6). Thus, NT-induced activation of the Erk pathway is
Ras-dependent.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 6.
NT-induced Erk activation is
Ras-dependent. NCM460-NTR1 cells were infected with
LacZ (Z)- or Ras-17N (R)-expressing retroviruses
and then incubated with M3D for 24 h before stimulated with NT
(10 7 M), PMA (2 µM), or EGF
(100 ng/ml) for 10 min. Cell lysates were used to determine the Erk1/2
phosphorylation as well as the total Erk2 (a protein loading control)
as described in Fig. 1a.
|
|
Because increased intracellular calcium is involved in angiotensin
(II)-induced Erk activation in vascular smooth muscle cells (44), we
tested the possibility that calcium participates in NT-induced Erk
activation. After pretreatment with BAPTAM/AM (50 µM) for
30 min, cells were treated with NT (10 7 M)
for 5 min. The data indicated that BAPTA/AM had no effect on NT-induced
Erk activation (n = 2 independent experiments, data not
shown). We also examined the effect of PTX on NT-induced Erk activation. NCM460-NTR1 cells were pretreated with PTX (100 ng/ml) overnight and treated with lysophosphatidic acid (50 µM)
or NT (10 7 M) for 10 min. The results (not
shown) indicated that PTX almost completely inhibited lysophosphatidic
acid-induced Erk activation but had no effect on NT-induced Erk
activation. Taken together, our results demonstrate that NT-stimulated
Erk activation is Ras-dependent but does not require
increased intracellular calcium and PTX-sensitive Gi/o proteins.
Dominant Negative Ras Inhibits NT-induced IL-8 Expression--
To
determine whether Ras activation is required for NT-induced IL-8
secretion and IL-8 gene transcription, NCM460-NTR1 cells were infected
with Ras-17N-expressing retroviral vectors and then exposed to NT
(10-7 M) for 4 h. Expression of the
dominant negative Ras significantly inhibited NT-induced IL-8 protein
release (Fig. 7a). To explore whether the Ras-17N mutant also inhibited NT-induced IL-8
transcription, cells were transfected with the Ras-17N construct along
with IL-8 promoter-luciferase construct and then exposed to NT
(10 7 M) for 4 h. As shown in Fig.
7b, overexpression of Ras-17N significantly inhibited
NT-stimulated IL-8 promoter activity.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 7.
Effect of dominant negative Ras on NT-induced
IL-8 expression. a, NCM460-NTR1 cells were infected
with Ras-17N- or LacZ-expressing retroviruses and then incubated with
M3D media for 24 h before exposed to NT (10 7
M) for 4 h. IL-8 was then measured in the conditioned
media by ELISA. Asterisk indicates p < 0.01, Ras-17N-expressing cells with NT stimulation versus
LacZ-expressing cells with NT stimulation. b, cells were
transiently transfected with Ras-17N construct or control LacZ plasmid
along with IL-8 promoter-luciferase construct. Cells were incubated
with M3D media for 24 h and then incubated with NT
(10 7 M) for 4 h, and luciferase activity
was measured. Asterisk indicates p < 0.001, Ras-17N-expressing cells with NT stimulation versus
LacZ-expressing cells with NT stimulation. The results are
representative of the three separate experiments.
|
|
 |
DISCUSSION |
We have reported previously (14, 15) that NTR1 are up-regulated in
colonic inflammation and presented indirect evidence for increased
expression of NTR1 receptors on colonic epithelial cells. This study
shows that NCM460 human colonic epithelial cells express the high
affinity NT receptor that mediates Erk activation in response to NT.
Moreover, exposure of NCM460 cells overexpressing NTR1 to NT caused
secretion of the potent chemoattractant IL-8 in a time- and
dose-dependent manner. NT-induced IL-8 secretion and gene
transcription were dependent on NF- B and Erk activation. In
addition, NT-mediated NF- B activation was mediated by intracellular calcium release. We also report here for the first time that NT stimulates Ras activity which is required for NT-induced Erk activation and that both calcium and Ras activation are involved in IL-8 release
in response to NT.
Our studies demonstrate that the mechanism of NF- B activation and
IL-8 secretion in response to NT in colonocytes is
calcium-dependent. Interestingly,
calcium-dependent NF- B activation is required for IL-8
expression induced by the neuropeptide substance P in human monocytes
(45). The mechanisms by which intracellular calcium release leads to
activation of NF- B activity following NT exposure have not been
elucidated. Exposure of cells to various stimuli such as cytokines
triggers a signaling cascade causing phosphorylation and subsequent
degradation of I B proteins leading to the release, activation, and
nuclear translocation of NF- B (46). The effect of increased
intracellular calcium on I B phosphorylation may be mediated by a
calcium-calmodulin-dependent pathway as W7, a
calmodulin-antagonist, can inhibit I B degradation (47, 48). In
addition, the calcium-dependent protein phosphatase
calcineurin may synergize with protein kinase C to activate NF- B by
a yet unknown mechanism (47, 49, 50). Our observation that W7 or
cyclosporin A partially inhibited NT-induce IL-8 secretion suggests
that multiple calcium-dependent pathways may be involved in
NF- B activation following NT exposure.
Our results indicate that Erk is required for NT-induced IL-8 promoter
activity and IL-8 production, supporting a proinflammatory role for MAP
kinases in the NTR1 signaling pathway. Previous results also support a
major role for MAP kinases in IL-8 secretion. For example, the
inhibitor of p38 MAP kinase, SB203580, and the inhibitor of MAP
kinase/Erk kinase, PD98059, significantly inhibited IL-8 release
induced by C. difficile toxin A in human monocytes (31) as
well as by Helicobacter pylori in gastric epithelial cells (33). Although both MAP kinase and NF- B are required for IL-8 gene
expression in response to many stimuli, involvement of MAP kinase
pathways in NF- B activation appears to be dependent on the
particular stimulus. For instance, Erk and p38 MAP kinase activation
following H. pylori exposure did not appear to be associated with NF- B stimulation (33). Similarly, in synovial fibroblasts the
p38 MAP kinase inhibitor SB203580 reduced IL-8 induction in response to
IL-1 without affecting nuclear translocation of NF- B (51).
However a RSK-MAPK-pp90rsk pathway was shown to be
required for Pseudomonas aeruginosa-induced NF- B-dependent gene expression and mucin overproduction
in epithelial cells (52). In addition, our results demonstrate that Erk
is also involved in NT-induced NF- B-dependent gene
expression as PD98059 inhibited NF- B-driven luciferase activity. In
addition to the NF- B site, the IL-8 promoter contains binding sites
for the transcription factors, AP-1 and C/EBP. Our experiments also indicate that the AP-1- and C/EBP-binding sites were involved in
NT-induced IL-8 promoter activity (data not shown). Along these lines,
a MAP kinase-dependent pathway is known to activate the transcriptional activity of AP-1 as well as expression of
c-jun and c-fos, the two subunits of the
transcriptional factor AP-1 (53, 54). Taken together, NT-mediated IL-8
expression in human colonocytes involves both NF- B and MAP
kinase-dependent pathways.
Although NT-stimulated Erk activation in Chinese hamster ovary cells
expressing NTR1 was partially inhibited by PTX and completely blocked
by the protein kinase C inhibitor GF 109203X (25), the pathway that
leads to Erk activation is not clear. Our results demonstrate that a
dominant negative Ras mutant Ras-17N completely inhibited NT-induced
Erk phosphorylation and significantly reduced NT-induced IL-8
expression. Moreover, NT stimulated Ras-GTP loading. To our knowledge,
this is the first report to show that NT activates Ras and that
NT-induced Erk activation is Ras-dependent. The exact mechanism whereby NT stimulates Ras-dependent Erk
activation in a Gi/o protein and calcium-independent manner
remains to be elucidated. It is known that Ras-dependent
Erk activation by GPCR can be mediated through multiple mechanisms. One
is PTX-sensitive Gi/o-dependent pathway in
which the  subunits released from activated Gi/o proteins recruit the protein-tyrosine kinase Src, leading to subsequent activation of the Ras-Erk pathway (55-57). Another pathway leading to
Ras-dependent Erk activation is via the
calcium-dependent tyrosine kinase Pyk2, which is triggered
by PTX-insensitive Gq and phospholipase C (58). However,
the inability of PTX or BAPTA/AM to affect NT-induced Erk activation in
our study indicates that these two pathways are unlikely to mediate
NT-induced Ras-dependent Erk activation. In addition,
transactivation of the EGF receptor has also been shown to mediate Erk
activation induced by many GPCRs such as the receptors for
lysophosphatidic acid, thrombin (59), and neuropeptide substance P
(60). The possibility that the transactivation of the EGF receptor is
involved in NT-induced Erk activation remains to be elucidated.
In summary, our findings that NT induces expression of pro-inflammatory
cytokine IL-8 via Ca2+-dependent NF- B and
Ras-dependent Erk activation further our understanding of
the molecular mechanism by which this neuropeptide mediates its
pro-inflammatory effect in the gastrointestinal tract.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Richard C. Mulligan, Dr. Steve
R. Farmer, and Dr. Debabrata Mukhopadhyay for kindly providing some of
plasmids used in this study. We would like to thank Sanofi Recherche
(Toulouse, France) for kindly providing the NTRI antagonist
SR-48692.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grants DK 33506 (to C. P.) and DK54920 (to C. P. K.) and by
the Crohn's and Colitis Foundation of America.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Recipient of Career Development award from the Crohn's and
Colitis Foundation of America.
¶
To whom correspondence should be addressed: Beth Israel
Deaconess Medical Center, Division of Gastroenterology, Dana 501, 330 Brookline Ave., Boston, MA 02215. Tel.: 617-667-1259; Fax: 617-667-5071; E-mail: cpothoul@caregroup.harvard.edu.
Published, JBC Papers in Press, September 26, 2001, DOI 10.1074/jbc.M104942200
 |
ABBREVIATIONS |
The abbreviations used are:
NT, neurotensin;
GPCR, guanine nucleotide-binding protein-coupled receptor;
Erk, extracellular signal-regulated protein kinase;
BAPTA/AM, 1,2-bis(o-aminophenooxy)ethane-N,N,N',N'-tetraacetic
acid, acetoxymethyl ester;
PMA, phorbol 12-myristate acetate;
PTX, pertussis toxin;
IL, interleukin;
NTR, neurotensin receptor;
EGF, epidermal growth factor;
RT-PCR, reverse transcriptase-polymerase chain
reaction;
bp, base pair;
FBS, fetal bovine serum;
PBS, phosphate-buffered saline;
ELISA, enzyme-linked immunosorbent assay;
EMSA, electrophoretic mobility shift assay(s);
MAP, mitogen-activated
protein.
 |
REFERENCES |
| 1.
|
Carraway, R.,
and Leeman, S. E.
(1973)
J. Biol. Chem.
248,
6854-6861
|
| 2.
|
Carraway, R.,
and Leeman, S. E.
(1976)
J. Biol. Chem.
251,
7045-7052
|
| 3.
|
Polak, J. M.,
Sullivan, S. N.,
Bloom, S. R.,
Buchan, A. M.,
Facer, P.,
Brown, M. R.,
and Pearse, A. G.
(1977)
Nature
270,
183-184
|
| 4.
|
Walsh, J. H.
(1987)
in
Physiology of the Gastrointestinal Tract
(Johnson, L. R., ed), 2nd Ed.
, pp. 181-253, Raven Press, Ltd., New York
|
| 5.
|
Thor, K.,
and Rosell, S.
(1986)
Gastroenterology
90,
27-31
|
| 6.
|
Riegler, M.,
Castagliuolo, I.,
Wang, C.,
Wlk, M.,
Sogukoglu, T.,
Wenzl, E.,
Matthews, J. B.,
and Pothoulakis, C.
(2000)
Gastroenterology
119,
348-357
|
| 7.
|
Wood, J. G.,
Hoang, H. D.,
Bussjaeger, L. J.,
and Solomon, T. E.
(1988)
Am. J. Physiol.
255,
G813-G817
|
| 8.
|
Wood, J. G.,
Hoang, H. D.,
Bussjaeger, L. J.,
and Solomon, T. E.
(1988)
Pancreas
3,
332-339
|
| 9.
|
Yoshinaga, K.,
Evers, B. M.,
Izukura, M.,
Parekh, D.,
Uchida, T.,
Townsend, C. M.,
and Thompson, J. C.
(1992)
Surg. Oncol.
1,
127-134
|
| 10.
|
Maoret, J. J.,
Anini, Y.,
Rouyer-Fessard, C.,
Gully, D.,
and Laburthe, M.
(1999)
Int. J. Cancer
80,
448-454
|
| 11.
|
Evers, B. M.,
Izukura, M.,
Chung, D. H.,
Parekh, D.,
Yoshinaga, K.,
Greeley, G. H.,
Uchida, T.,
Townsend, C. M.,
and Thompson, J. C.
(1992)
Gastroenterology
103,
86-91
|
| 12.
|
Vincent, J. P.,
Mazella, J.,
and Kitabgi, P.
(1999)
Trends Pharmacol. Sci.
20,
302-309
|
| 13.
|
Castagliuolo, I.,
Leeman, S. E.,
Bartolak-Suki, E.,
Nikulasson, S.,
Qiu, B.,
Carraway, R. E.,
and Pothoulakis, C.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
12611-12615
|
| 14.
|
Castagliuolo, I.,
Wang, C. C.,
Valenick, L.,
Pasha, A.,
Nikulasson, S.,
Carraway, R. E.,
and Pothoulakis, C.
(1999)
J. Clin. Invest.
103,
843-849
|
| 15.
|
Castagliuolo, I.,
Valenick, L.,
Pasha, A.,
Sturniolo, G. C.,
D'Incá, R. D.,
Fiocchi, C.,
and Pothoulakis, C.
(1999)
Gastroenterology
116,
799
|
| 16.
|
Pothoulakis, C.,
Castagliuolo, I.,
and Leeman, S. E.
(1998)
Ann. N.Y. Acad. Sci.
840,
635-648
|
| 17.
|
Miller, L. A.,
Cochrane, D. E.,
Carraway, R. E.,
and Feldberg, R. S.
(1995)
Br. J. Pharmacol.
114,
1466-1470
|
| 18.
|
Goldman, R.,
Bar-Shavit, Z.,
and Romeo, D.
(1983)
FEBS Lett.
159,
63-67
|
| 19.
|
Schaeffer, P.,
Laplace, M. C.,
Savi, P.,
Pflieger, A. M.,
Gully, D.,
and Herbert, J. M.
(1995)
J. Biol. Chem.
270,
3409-3413
|
| 20.
|
Lemaire, I.
(1988)
J. Immunol.
140,
2983-2988
|
| 21.
|
Ehlers, R. A.,
Bonnor, R. M.,
Wang, X.,
Hellmich, M. R.,
and Evers, B. M.
(1998)
Surgery
124,
239-246
|
| 22.
|
Ehlers, R. A.,
Zhang, Y.,
Hellmich, M. R.,
and Evers, B. M.
(2000)
Biochem. Biophys. Res. Commun.
269,
704-708
|
| 23.
|
Amar, S.,
Kitabgi, P.,
and Vincent, J. P.
(1986)
FEBS Lett.
201,
31-36
|
| 24.
|
Bozou, J. C.,
Rochet, N.,
Magnaldo, I.,
Vincent, J. P.,
and Kitabgi, P.
(1989)
Biochem. J.
264,
871-878
|
| 25.
|
Poinot-Chazel, C.,
Portier, M.,
Bouaboula, M.,
Vita, N.,
Pecceu, F.,
Gully, D.,
Monroe, J. G.,
Maffrand, J. P.,
Le Fur, G.,
and Casellas, P.
(1996)
Biochem. J.
320,
145-151
|
| 26.
|
Schmid, R. M.,
Adler, G.,
and Liptay, S.
(1998)
Gut
43,
587-588
|
| 27.
|
Ellis, R. D.,
Goodlad, J. R.,
Limb, G. A.,
Powell, J. J.,
Thompson, R. P.,
and Punchard, N. A.
(1998)
Inflamm. Res.
47,
440-445
|
| 28.
|
Ardite, E.,
Panes, J.,
Miranda, M.,
Salas, A.,
Elizalde, J. I.,
Sans, M.,
Arce, Y.,
Bordas, J. M.,
Fernandez-Checa, J. C.,
and Pique, J. M.
(1998)
Br. J. Pharmacol.
124,
431-433
|
| 29.
|
Papadakis, K. A.,
and Targan, S. R.
(2000)
Annu. Rev. Med.
51,
289-298
|
| 30.
|
Linevsky, J. K.,
Pothoulakis, C.,
Keates, S.,
Warny, M.,
Keates, A. C.,
Lamont, J. T.,
and Kelly, C. P.
(1997)
Am. J. Physiol.
273,
G1333-G1340
|
| 31.
|
Warny, M.,
Keates, A. C.,
Keates, S.,
Castagliuolo, I.,
Zacks, J. K.,
Aboudola, S.,
Qamar, A.,
Pothoulakis, C.,
LaMont, J. T.,
and Kelly, C. P.
(2000)
J. Clin. Invest.
105,
1147-1156
|
| 32.
|
Bliss, C. M., Jr.,
Golenbock, D. T.,
Keates, S.,
Linevsky, J. K.,
and Kelly, C. P.
(1998)
Infect. Immun.
66,
5357-5363
|
| 33.
|
Keates, S.,
Keates, A. C.,
Warny, M.,
Peek, R. M.,
Murray, P. G.,
and Kelly, C. P.
(1999)
J. Immunol.
163,
5552-5559
|
| 34.
|
Okamoto, S.,
Mukaida, N.,
Yasumoto, K.,
Rice, N.,
Ishikawa, Y.,
Horiguchi, H.,
Murakami, S.,
and Matsushima, K.
(1994)
J. Biol. Chem.
269,
8582-8589
|
| 35.
|
Wu, G. D.,
Lai, E. J.,
Huang, N.,
and Wen, X.
(1997)
J. Biol. Chem.
272,
2396-2403
|
| 36.
|
Chomczynski, P.,
and Sacchi, N.
(1987)
Anal. Biochem.
162,
156-159
|
| 37.
|
Vita, N.,
Laurent, P.,
Lefort, S.,
Chalon, P.,
Dumont, X.,
Kaghad, M.,
Gully, D.,
Le Fur, G.,
Ferrara, P.,
and Caput, D.
(1993)
FEBS Lett.
317,
139-142
|
| 38.
|
Fried, M.,
and Crothers, D. M.
(1981)
Nucleic Acids Res.
9,
6505-6525
|
| 39.
|
Moyer, M. P.,
Manzano, L. A.,
Merriman, R. L.,
Stauffer, J. S.,
and Tanzer, L. R.
(1996)
In Vitro Cell. Dev. Biol. Anim.
32,
315-317
|
| 40.
|
Taylor, S. J.,
and Shalloway, D.
(1996)
Curr. Biol.
6,
1621-1627
|
| 41.
|
Takeda, H.,
Matozaki, T.,
Takada, T.,
Noguchi, T.,
Yamao, T.,
Tsuda, M.,
Ochi, F.,
Fukunaga, K.,
Inagaki, K.,
and Kasuga, M.
(1999)
EMBO J.
18,
386-395
|
| 42.
|
Blaukat, A.,
Barac, A.,
Cross, M. J.,
Offermanns, S.,
and Dikic, I.
(2000)
Mol. Cell. Biol.
20,
6837-6848
|
| 43.
|
Ueda, Y.,
Hirai, S.,
Osada, S.,
Suzuki, A.,
Mizuno, K.,
and Ohno, S.
(1996)
J. Biol. Chem.
271,
23512-23519
|
| 44.
|
Lucchesi, P. A.,
Bell, J. M.,
Willis, L. S.,
Byron, K. L.,
Corson, M. A.,
and Berk, B. C.
(1996)
Circ. Res.
78,
962-970
|
| 45.
|
Lieb, K.,
Fiebich, B. L.,
Berger, M.,
Bauer, J.,
and Schulze-Osthoff, K.
(1997)
J. Immunol.
159,
4952-4958
|
| 46.
|
Baldwin, A. S.
(1996)
Annu. Rev. Immunol.
14,
649-683
|
| 47.
|
Mattila, P. S.,
Ullman, K. S.,
Fiering, S.,
Emmel, E. A.,
McCutcheon, M.,
Crabtree, G. R.,
and Herzenberg, L. A.
(1990)
EMBO J.
9,
4425-4433
|
| 48.
|
Hughes, K.,
Antonsson, A.,
and Grundstrom, T.
(1998)
FEBS Lett.
441,
132-136
|
| 49.
|
Steffan, N. M.,
Bren, G. D.,
Frantz, B.,
Tocci, M. J.,
O'Neill, E. A.,
and Paya, C. V.
(1995)
J. Immunol.
155,
4685-4691
|
| 50.
|
Trushin, S. A.,
Pennington, K. N.,
Algeciras-Schimnich, A.,
and Paya, C. V.
(1999)
J. Biol. Chem.
274,
22923-22931
|
| 51.
|
Suzuki, M.,
Tetsuka, T.,
Yoshida, S.,
Watanabe, N.,
Kobayashi, M.,
Matsui, N.,
and Okamoto, T.
(2000)
FEBS Lett.
465,
23-27
|
| 52.
|
Li, J. D.,
Feng, W.,
Gallup, M.,
Kim, J. H.,
Gum, J.,
Kim, Y.,
and Basbaum, C.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
5718-5723
|
| 53.
|
Hsu, T. C.,
Young, M. R.,
Cmarik, J.,
and Colburn, N. H.
(2000)
Free Radic. Biol. Med.
28,
1338-1348
|
| 54.
|
Whitmarsh, A. J.,
and Davis, R. J.
(1996)
J. Mol. Med.
74,
589-607
|
| 55.
|
Koch, W. J.,
Hawes, B. E.,
Allen, L. F.,
and Lefkowitz, R. J.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
12706-12710
|
| 56.
|
Crespo, P.,
Xu, N.,
Simonds, W. F.,
and Gutkind, J. S.
(1994)
Nature
369,
418-420
|
| 57.
|
Luttrell, L. M.,
Ferguson, S. S.,
Daaka, Y.,
Miller, W. E.,
Maudsley, S.,
Della Rocca, G. J.,
Lin, F.,
Kawakatsu, H.,
Owada, K.,
Luttrell, D. K.,
Caron, M. G.,
and Lefkowitz, R. J.
(1999)
Science
283,
655-661
|
| 58.
|
Dikic, I.,
Tokiwa, G.,
Lev, S.,
Courtneidge, S. A.,
and Schlessinger, J.
(1996)
Nature
383,
547-550
|
| 59.
|
Daub, H.,
Weiss, F. U.,
Wallasch, C.,
and Ullrich, A.
(1996)
Nature
379,
557-560
|
| 60.
|
Castagliuolo, I.,
Valenick, L.,
Liu, J.,
and Pothoulakis, C.
(2000)
J. Biol. Chem.
275,
26545-26550
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H.-W. Koon, Y. S. Kim, H. Xu, A. Kumar, D. Zhao, I. Karagiannides, P. R. Dobner, and C. Pothoulakis
Neurotensin induces IL-6 secretion in mouse preadipocytes and adipose tissues during 2,4,6,-trinitrobenzensulphonic acid-induced colitis
PNAS,
May 26, 2009;
106(21):
8766 - 8771.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E Kokkotou, D O Espinoza, D Torres, I Karagiannides, S Kosteletos, T Savidge, M O'Brien, and C Pothoulakis
Melanin-concentrating hormone (MCH) modulates C difficile toxin A-mediated enteritis in mice
Gut,
January 1, 2009;
58(1):
34 - 40.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Kokkotou, A. C. Moss, D. Torres, I. Karagiannides, A. Cheifetz, S. Liu, M. O'Brien, E. Maratos-Flier, and C. Pothoulakis
Melanin-concentrating hormone as a mediator of intestinal inflammation
PNAS,
July 29, 2008;
105(30):
10613 - 10618.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. C Moss, P. Anton, T. Savidge, P. Newman, A. S Cheifetz, J. Gay, S. Paraschos, M. W. Winter, M. P Moyer, K. Karalis, et al.
Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2{alpha}
Gut,
September 1, 2007;
56(9):
1210 - 1217.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Li, K. L. O'Connor, X. Cheng, F. C. Mei, T. Uchida, C. M. Townsend Jr, and B. M. Evers
Cyclic Adenosine 5'-Monophosphate-Stimulated Neurotensin Secretion Is Mediated through Rap1 Downstream of both Epac and Protein Kinase A Signaling Pathways
Mol. Endocrinol.,
January 1, 2007;
21(1):
159 - 171.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. S. Kim, V. Rajagopal, C. Gonsalves, C. Johnson, and V. K. Kalra
A Novel Role of Hypoxia-Inducible Factor in Cobalt Chloride- and Hypoxia-Mediated Expression of IL-8 Chemokine in Human Endothelial Cells
J. Immunol.,
November 15, 2006;
177(10):
7211 - 7224.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Wang, Q. Wang, K. L. Ives, and B. M. Evers
Curcumin Inhibits Neurotensin-Mediated Interleukin-8 Production and Migration of HCT116 Human Colon Cancer Cells.
Clin. Cancer Res.,
September 15, 2006;
12(18):
5346 - 5355.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Souaze, S. Dupouy, V. Viardot-Foucault, E. Bruyneel, S. Attoub, C. Gespach, A. Gompel, and P. Forgez
Expression of Neurotensin and NT1 Receptor in Human Breast Cancer: A Potential Role in Tumor Progression.
Cancer Res.,
June 15, 2006;
66(12):
6243 - 6249.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Karagiannides, E. Kokkotou, M. Tansky, T. Tchkonia, N. Giorgadze, M. O'Brien, S. E. Leeman, J. L. Kirkland, and C. Pothoulakis
Induction of colitis causes inflammatory responses in fat depots: Evidence for substance P pathways in human mesenteric preadipocytes
PNAS,
March 28, 2006;
103(13):
5207 - 5212.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kim, S. H. Rhee, E. Kokkotou, X. Na, T. Savidge, M. P. Moyer, C. Pothoulakis, and J. T. LaMont
Clostridium difficile Toxin A Regulates Inducible Cyclooxygenase-2 and Prostaglandin E2 Synthesis in Colonocytes via Reactive Oxygen Species and Activation of p38 MAPK
J. Biol. Chem.,
June 3, 2005;
280(22):
21237 - 21245.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Zhao, Y. Zhan, H. Zeng, H.-W. Koon, M. P. Moyer, and C. Pothoulakis
Neurotensin Stimulates Interleukin-8 Expression through Modulation of I{kappa}B{alpha} Phosphorylation and p65 Transcriptional Activity: Involvement of Protein Kinase C{alpha}
Mol. Pharmacol.,
June 1, 2005;
67(6):
2025 - 2031.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Zhao, Y. Zhan, H. W. Koon, H. Zeng, S. Keates, M. P. Moyer, and C. Pothoulakis
Metalloproteinase-dependent Transforming Growth Factor-{alpha} Release Mediates Neurotensin-stimulated MAP Kinase Activation in Human Colonic Epithelial Cells
J. Biol. Chem.,
October 15, 2004;
279(42):
43547 - 43554.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. H. Rhee, A. C. Keates, M. P. Moyer, and C. Pothoulakis
MEK Is a Key Modulator for TLR5-induced Interleukin-8 and MIP3{alpha} Gene Expression in Non-transformed Human Colonic Epithelial Cells
J. Biol. Chem.,
June 11, 2004;
279(24):
25179 - 25188.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Weiss, I. Shalit, H. Blau, S. Werber, D. Halperin, A. Levitov, and I. Fabian
Anti-Inflammatory Effects of Moxifloxacin on Activated Human Monocytic Cells: Inhibition of NF-{kappa}B and Mitogen-Activated Protein Kinase Activation and of Synthesis of Proinflammatory Cytokines
Antimicrob. Agents Chemother.,
June 1, 2004;
48(6):
1974 - 1982.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Toy-Miou-Leong, C. L. Cortes, A. Beaudet, W. Rostene, and P. Forgez
Receptor Trafficking via the Perinuclear Recycling Compartment Accompanied by Cell Division Is Necessary for Permanent Neurotensin Cell Sensitization and Leads to Chronic Mitogen-activated Protein Kinase Activation
J. Biol. Chem.,
March 26, 2004;
279(13):
12636 - 12646.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Yoshida, A. Kumar, Y. Koyama, H. Peng, A. Arman, J. A. Boch, and P. E. Auron
Interleukin 1 Activates STAT3/Nuclear Factor-{kappa}B Cross-talk via a Unique TRAF6- and p65-dependent Mechanism
J. Biol. Chem.,
January 16, 2004;
279(3):
1768 - 1776.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Zhao, S. Kuhnt-Moore, H. Zeng, J. S. Wu, M. P. Moyer, and C. Pothoulakis
Neurotensin stimulates IL-8 expression in human colonic epithelial cells through Rho GTPase-mediated NF-kappa B pathways
Am J Physiol Cell Physiol,
June 1, 2003;
284(6):
C1397 - C1404.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Simeonidis, I. Castagliuolo, A. Pan, J. Liu, C.-C. Wang, A. Mykoniatis, A. Pasha, L. Valenick, S. Sougioultzis, D. Zhao, et al.
Regulation of the NK-1 receptor gene expression in human macrophage cells via an NF-kappa B site on its promoter
PNAS,
March 4, 2003;
100(5):
2957 - 2962.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Martin, J.-P. Vincent, and J. Mazella
Involvement of the Neurotensin Receptor-3 in the Neurotensin-Induced Migration of Human Microglia
J. Neurosci.,
February 15, 2003;
23(4):
1198 - 1205.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Zeng, D. Zhao, and D. Mukhopadhyay
KDR Stimulates Endothelial Cell Migration through Heterotrimeric G Protein Gq/11-mediated Activation of a Small GTPase RhoA
J. Biol. Chem.,
November 22, 2002;
277(48):
46791 - 46798.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Osawa, M. Nagaki, Y. Banno, D. A. Brenner, T. Asano, Y. Nozawa, H. Moriwaki, and S. Nakashima
Tumor Necrosis Factor Alpha-Induced Interleukin-8 Production via NF-{kappa}B and Phosphatidylinositol 3-Kinase/Akt Pathways Inhibits Cell Apoptosis in Human Hepatocytes
Infect. Immun.,
November 1, 2002;
70(11):
6294 - 6301.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. H. Nemeth, E. A. Deitch, C. Szabo, and G. Hasko
Hyperosmotic Stress Induces Nuclear Factor-{kappa}B Activation and Interleukin-8 Production in Human Intestinal Epithelial Cells
Am. J. Pathol.,
September 1, 2002;
161(3):
987 - 996.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Graness, C. E. Chwieralski, D. Reinhold, L. Thim, and W. Hoffmann
Protein Kinase C and ERK Activation Are Required for TFF- peptide-stimulated Bronchial Epithelial Cell Migration and Tumor Necrosis Factor-alpha -induced Interleukin-6 (IL-6) and IL-8 Secretion
J. Biol. Chem.,
May 17, 2002;
277(21):
18440 - 18446.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Zeng, D. Zhao, and D. Mukhopadhyay
Flt-1-mediated Down-regulation of Endothelial Cell Proliferation through Pertussis Toxin-sensitive G Proteins, beta gamma Subunits, Small GTPase CDC42, and Partly by Rac-1
J. Biol. Chem.,
February 1, 2002;
277(6):
4003 - 4009.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|